National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Trial Pipeline
Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors
NCT06819189
Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder
NCT06269627
Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms
NCT06484075
Individual Variations of Taste and Smell Perception in Alcohol Use Disorder (AUD)
NCT05677321
Mechanisms Underlying Individual Variations of Taste and Smell in Obesity
NCT04714892
Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
NCT04781322
COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study
NCT04391816
Nicotinic Receptor Genetic Variation and Alcohol Reward
NCT03294460
Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)
NCT03407079
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
NCT02535702
NIAAA Natural History Protocol
NCT02231840
Characterization Imaging Instruments in Alcoholics and Non-Alcoholics
NCT02108080
Behavioral and Functional Task Development, Implementation, and Testing
NCT02108054
Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI
NCT03326245
Human Laboratory Study of Varenicline for Alcohol Use Disorder
NCT03035708
HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder
NCT02252536
Brain Inflammation and Function in Alcoholism
NCT02233868
Neural Substrates of Approach-Avoidance Conflict
NCT02119624
A Novel Compound for Alcoholism Treatment
NCT02039349
Baclofen for Treating Anxiety and Alcoholism
NCT01751386
Computer-Assisted Self-Administration of Ethanol
NCT00713492
The Effect of Naltrexone on Alcohol Craving and on Brain Activity During Alcohol Infusion
NCT00667771
Aripiprazole and Topiramate on Free-Choice Alcohol Use
NCT00884884
Effect of LY686017 on Alcohol Craving
NCT00310427
Influence of Age and Sex on Alcohol Metabolism and Acute Responses
NCT00070577
Hangover, Congeners, Sleep and Occupational Performance
NCT00247585
A Placebo-Controlled Trial of Memantine for Alcohol Dependence
NCT00246415
Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron)
NCT00027079
Effect of Polyunsaturated Fatty Acids on Cardiovascular and Motor Responses Under Stress
NCT00014027
Drug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine)
NCT00006204
The Effect of Positive and Negative Emotions on Brain Activity in Alcoholics and Nonalcoholics
NCT00001675
Ondansetron Treatment for Alcoholism
NCT00000443
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 66 |
| Phase 2 | 9 |
| Phase 4 | 2 |
Therapeutic Areas
What the Pipeline for National Institute on Alcohol Abuse and Alcoholism (NIAAA) Shows
According to the ClinicalTrials.gov registry, National Institute on Alcohol Abuse and Alcoholism (NIAAA) is linked to 118 US clinical trials across every stage of research activity. Of those, 99 studies are currently recruiting — about 84% of the sponsor's indexed portfolio — and 19 are already marked complete, representing roughly 16% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for National Institute on Alcohol Abuse and Alcoholism (NIAAA) reports 2 late-stage studies (Phase 3 and Phase 4 combined) and 75 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for National Institute on Alcohol Abuse and Alcoholism (NIAAA) is Alcoholism with 11 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.